Get the Daily Brief
Latest Biotech News
US Cuts to mRNA Vaccine Funding Spark Pandemic Preparedness Concerns
The U.S. Department of Health and Human Services' decision to reduce funding for mRNA vaccine research has drawn criticism from the scientific community. Experts warn that this cut could weaken...
Anocca Raises $46M to Advance KRAS-Targeted Pancreatic Cancer Therapy
Swedish biotech firm Anocca secured $46 million to support clinical development of VIDAR-1, a nonviral genome-edited T-cell receptor (TCR) T-cell therapy targeting mutant KRAS in pancreatic ductal...
Genentech Ends Cell Therapy Collaboration with Adaptive Biotechnologies
Roche’s Genentech has terminated its multi-year collaboration with Adaptive Biotechnologies on cancer cell therapy development, ending a partnership valued at up to $2 billion. The alliance...
Novo Nordisk’s Wegovy Receives FDA Nod for Metabolic Liver Disease
The FDA granted accelerated approval to Novo Nordisk’s Wegovy for adults with metabolic dysfunction-associated steatohepatitis (MASH) featuring moderate-to-advanced liver fibrosis. This marks...
Reunion Neuroscience’s Psychedelic Drug Advances in Postpartum Depression
Reunion Neuroscience reported successful Phase 2 results for its short-acting psychedelic candidate RE104 in treating postpartum depression. The drug, functionally similar to psilocybin,...
Skyhawk and Merck KGaA Ink $2 Billion RNA Neurological Pact
RNA-targeting biotech Skyhawk Therapeutics entered a collaboration with Merck KGaA focused on neurological diseases, potentially worth $2 billion. Utilizing Skyhawk’s RNA splicing platform...
Stealth BioTherapeutics Pursues FDA Approval Amid Rare Disease Challenges
Stealth BioTherapeutics has resubmitted a new drug application for its Barth syndrome treatment following an FDA rejection. The company faces regulatory hurdles in generating sufficient data for...
Advanced AI-Designed Nanoparticles Propel Next-Gen RNA Therapies
Researchers at MIT unveiled a novel AI-driven approach to design lipid nanoparticles (LNPs) that enhance RNA vaccine and therapeutic delivery. The Composite Material Transformer (COMET) machine...
New Insights Into Treatment Resistance and Molecular Targets in Cancer
Multiple studies have illuminated mechanisms contributing to cancer treatment resistance and progression. Research from Garvan Institute identified suppression of JNK pathway driving estrogen...
Immunotherapy Advances in Lung Cancer with Liver Metastases
A recent systematic review and network meta-analysis evaluate immune checkpoint inhibitor (ICI) combinations for driver gene-negative non-small cell lung cancer patients presenting with liver...
Adaptive Biotechnologies, Genentech End Cancer Cell Therapy Pact
Adaptive Biotechnologies and Genentech will conclude their nearly six-and-a-half-year collaboration to develop personalized cancer cell therapies. The partnership used Adaptive’s T cell receptor...
Novo Nordisk’s Wegovy Clears FDA for Fatty Liver Disease
Novo Nordisk’s weight loss drug Wegovy received accelerated FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH), a prevalent liver condition. Phase 3 trials...
Skyhawk and Merck KGaA Ink $2 Billion Neurological RNA Pact
Skyhawk Therapeutics and Merck KGaA announced a collaboration aiming to develop RNA splicing modulators targeting neurological diseases, with potential payments up to $2 billion. Skyhawk will...
Anocca Scores $46 Million to Pursue Pancreatic Cancer Cell Therapy
Swedish biotech Anocca secured roughly $46 million (SEK 440 million) to support clinical trials of VIDAR-1, its nonviral genome-edited TCR T-cell therapy targeting mutant KRAS in pancreatic...
AI-Driven Nanoparticles Accelerate RNA Therapy Development
A team at MIT developed COMET, an AI-powered platform utilizing transformer neural networks to design lipid nanoparticles that improve RNA delivery efficacy across various cell types. Published in...
Stealth BioTherapeutics Shares FDA Rejection to Rally Support
In an unusual move, Stealth BioTherapeutics publicly disclosed an FDA rejection letter concerning its Barth syndrome treatment. The biotech is campaigning to garner regulatory reconsideration,...
Breakthroughs in Breast Cancer and Glioma Molecular Research
New studies provide insights into cancer mechanisms and potential therapies. A large multi-center retrospective study found that ovarian function suppression improves outcomes in premenopausal...
Insmed’s First Drug for Non-CF Bronchiectasis Gains FDA Nod
Insmed received FDA approval for Brinsupri (brensocatib), the first therapy for non-cystic fibrosis bronchiectasis, addressing neutrophilic inflammation to reduce exacerbations. The approval...
Pfizer's Sickle Cell Drug Fails Phase 3 Endpoint
Pfizer’s inclacumab, a P-selectin inhibitor acquired from Global Blood Therapeutics, failed to meet primary efficacy endpoint in a Phase 3 study targeting vaso-occlusive crises in sickle cell...
US Government Cuts mRNA Vaccine Research Funding: Consequences
Recent reductions in U.S. government funding for mRNA vaccine research raise concerns about impacts on healthcare innovation and biotech R&D. The funding cuts may slow the advancement of mRNA...